Take innovation as the driving force and quality as the lifeline

API production base completed and trial production completed

At the end of May 2023, Risen-Sun Pharma's API production base, Risen-Sun Pharmaceutical, completed trial production.

Class I innovative drug approved for clinical use

In February 2023, the Class I innovative drug W1302 project was approved for clinical trials.

AEO Customs Advanced Certification

In January 2022, Risen-Sun Pharma passed AEO Customs Advanced Certification.

New API production base

In March 2021,Risen-Sun Pharma's API production base, Risen-Sun Pharmaceutical, located in Ningyang Chemical Park, Ciyao Town, started construction.

Class I innovative drug development

In January 2021, it signed a contract with the Chinese Academy of Medical Sciences Union Institute of Materia Medica to introduce the Class I innovative drug W1302 project.

Establish R&D branch center

In August 2017, Beijing Fengke Research Institute started operation; in May 2020, Jinan Taihe Research Institute started operation; in August 2021, Jinan Tianrui Research Institute started operation.

Technology platform construction

In December 2014, it was certified as "Shandong Enterprise Technology Center"; in June 2017, it was certified as "Shandong Inhalation Preparation Engineering Laboratory"; in December 2019, it established a "Particulate Preparation Joint Laboratory" with Jinan University; in September 2020 Established a "Chemical Synthesis Joint Laboratory" with Shandong First Medical University.

Strategic cooperation with Xi'an Janssen

In November 2011, the company signed a strategic cooperation agreement with Xi'an Janssen Pharmaceutical Co., Ltd. in Beijing for "Daconine-Terbinafine Spray".

High-tech enterprise certification

In September 2010, the company passed the certification of "National High-tech Enterprise" and has continuously passed re-examinations.

EHS system certification

In June 2010, the company passed the international certification of ISO14001 environmental management system and ISO45001 occupational health and safety management "dual system" for the first time, and has continuously passed re-certification.

Information construction

In December 2006, Oracle ERP was launched (Jewim Pharmaceutical was the first domestic pharmaceutical company to launch Oracle ERP); in May 2021, the WMS system and new OA were launched; in November 2022, the smart energy management system (EMS) was launched.

Phase-out of Freons (CFCs) in inhalation aerosols

In June 2010, the Chinese government launched an action plan to phase out chlorofluorocarbon substances (CFCS) in medicinal inhalation aerosols. As the largest inhalation aerosol manufacturer in China, the company was the first in China to achieve the complete elimination of CFCs in pharmaceutical aerosols in December 2012. Therefore, in September 2017, it was awarded the United Nations Development Program, United Nations Environment Program, The certificate of recognition for "valuable contributions and efforts to protect the ozone layer" jointly issued by the United Nations Industrial Development Organization, the World Bank, and the Foreign Cooperation Center of the Ministry of Ecology and Environment.

Exclusive new drug approved

In October 2004, the new drug diclofenac sodium spray was released for the treatment of oral ulcers; in May 2011, the new antifungal drug suoconazole nitrate spray was released; in October 2013, the new anti-migraine drug zolmitriptan nasal spray was released.

First generic drug approved

In December 1996, nitroglycerin aerosol; in September 2008, escitalopram oxalate tablets; in July 2011, beclomethasone propionate nasal aerosol; in September 2011, albuterol sulfate inhalation aerosol ; In September 2012, beclomethasone propionate inhalation aerosol; in January 2018, ipratropium bromide inhalation solution.

International GMP certification

In June 2004, it obtained the first international GMP certificate and has successively passed GMP certifications in more than 20 overseas countries. In June 2013, it passed the Australian Therapeutic Goods Administration (TGA) GMP certification with the highest standard A1 level, and passed re-certification in 2016 and 2021.

Factory was first built

In March 2002, the company built an aerosol factory in Taishan District, Tai'an and put it into production in August 2003. In March 2004, the company built a comprehensive main factory in Tai'an High-tech Zone and put it into production in February 2009. In March 2021, the company built an API factory in Ningyang Chemical Industry Park, Tai'an.

Company registration

In December 1993, the company's predecessor, "Shandong Yangtai Pharmaceutical Co., Ltd." was registered and established. In August 2001, "Beijing Zhendong Pharmaceutical" merged with "Shandong Yangtai" and the company was renamed "Shandong Jingwei Pharmaceutical Co., Ltd.".